ClinicalTrials.gg
CompletedNCT04419506Updated Nov 1, 2022Results posted

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of BI 1015550 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 75 sites in 22 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim — 1 open to participants now, 3 under way, 1 of them phase 3. Idiopathic Pulmonary Fibrosis · Boehringer Ingelheim.

Enrollment
8th of 18
147 · median 109
Started
2020
the only one that year
Phase 2
7 of 36
1 open now
Registered
21st of 36
by date

Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 7 in phase 2, and was the 21st registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study.

The purpose of the study is to find out whether a medicine called BI 1015550 can slow down the worsening of lung function. Participants are in the study for about 4 months. During this time, they visit the study site about 7 times. At the beginning, they visit the study site every 2 weeks.

After 1 month of treatment, they visit the study site every 4 weeks.

The participants are put into 2 groups by chance. 1 group gets BI 1015550. The other group gets placebo. Placebo tablets look like BI 1015550 tablets but contain no medicine. The participants take BI 1015550 or placebo tablets twice a day.

The participants have lung function tests at study visits. The results of the lung function tests are compared between the BI 1015550 group and the placebo group. The doctors also regularly check the general health of the participants.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥40 years when signing the .
  2. Diagnosis:

    1. IPF based on 2018 ATS/ERS/JRS/ALAT Guideline as confirmed by the investigator based on chest High Resolution Computed Tomography Scan (HRCT) scan taken within 12 months of Visit 1 and if available surgical lung .

      and

    2. Usual interstitial pneumonia (UIP) or probable UIP HRCT pattern consistent with the clinical diagnosis of IPF, as confirmed by central review prior to Visit 2*

      • if indeterminate HRCT finding IPF may be confirmed locally by (historical) biopsy
  3. Stable for at least 8 weeks prior to Visit 1. Patients have to be either :

    • not on therapy with nintedanib or pirfenidone for at least 8 weeks prior to Visit 1 (combination of nintedanib plus pirfenidone not allowed), or
    • on stable* therapy with nintedanib or pirfenidone for at least 8 weeks prior to Visit 1 and planning to stay stable on this background therapy after randomisation.

    [*stable therapy is defined as the individually and general tolerated regimen of either pirfenidone or nintedanib]

  4. Forced Vital Capacity (FVC) ≥45% of predicted normal at Visit 1
  5. Diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for [Hb] [Visit 1]) ≥ 25% to \< 80% of predicted normal at Visit 1.
  6. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.

Exclusion criteria

Exclusion Criteria:

  1. Relevant airways obstruction (pre-bronchodilator (FEV1)/Forced Vital Capacity (FVC) \< 0.7) at Visit 1.
  2. In the opinion of the Investigator, other pulmonary abnormalities.
  3. Acute IPF exacerbation within 4 months prior to screening and/or during the screening period (investigator-determined).
  4. Lower respiratory tract infection requiring antibiotics within 4 weeks prior to Visit 1 and/or during the screening period.
  5. Major surgery (major according to the investigator's assessment) performed within 3 months prior to Visit 1 or planned during the course of the trial. (Being on a transplant list is allowed).
  6. Any documented active or suspected or history of malignancy within 5 years prior to Visit 1, except appropriately treated basal cell carcinoma of the skin, "under surveillance" prostate cancer or in situ carcinoma of uterine cervix.
  7. Evidence of active infection (chronic or acute) based on clinical exam or laboratory findings at Visit 1 or at Visit 2.
  8. Any suicidal behaviour in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
  9. The patient has a confirmed infection with SARS-CoV-2 within the 4 weeks prior to Visit 1 and/or during the screening period.

Further exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
147 participants (actual)

Study arms

  • Placebo comparator
    Placebo, Antifibrotics at baseline

    Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.

    Drug: Placebo

  • Experimental
    BI 1015550, Antifibrotics at baseline

    Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.

    Drug: BI 1015550

  • Placebo comparator
    Placebo, Non-antifibrotics at baseline

    Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.

    Drug: Placebo

  • Experimental
    BI 1015550, Non-antifibrotics at baseline

    Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.

    Drug: BI 1015550

Interventions

  • 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.

  • DrugPlacebo

    placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.

06

What researchers measure

Primary outcomes

  1. The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks

    The change from baseline in Forced vital capacity (FVC) at 12 weeks. Data were analysed with a restricted maximum likelihood (REML)-based approach using a mixed model with repeated measures (MMRM). The analysis included the fixed, categorical effect of treatment at each visit, and the fixed, continuous effects of baseline FVC at each visit. Visit was treated as the repeated measure, with an unstructured covariance structure used to model the within-patient measurements.

    Time frame: Baseline (day 1) and week 12.

Secondary outcomes

  1. The Number of Patients With Treatment Emergent Adverse Event

    The number of patients with any adverse event during the on-treatment period.

    Time frame: From the start of treatment till the end of treatment + 7 days residual effect period, an average of 87.4 days.

07

Results

Posted Nov 1, 2022

Participant flow

This was a trial with a randomised, placebo-controlled, double-blind, parallel-group design over 12 weeks, including a screening period of up to 44 days, a 12-week treatment period, and a 1-week follow-up period in patients with idiopathic pulmonary fibrosis (IPF) stratified by baseline antifibrotic treatment (Non-AF stratum: patients not on antifibrotic treatment at baseline; AF stratum: stable antifibrotic treatment with nintedanib or pirfenidone at baseline).

Participant flow — Overall Study
MilestonePlacebo - Antifibrotics at BaselineBI 1015550 - Antifibrotics at BaselinePlacebo - Non-antifibrotics at BaselineBI 1015550 - Non-antifibrotics at Baseline
Started25492548
Completed25392543
Not completed01005
Withdrew: Adverse event01003
Withdrew: Withdrawal by subject0001
Withdrew: Poor-compliance0001

Outcome measures

PrimaryThe Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks

The change from baseline in Forced vital capacity (FVC) at 12 weeks. Data were analysed with a restricted maximum likelihood (REML)-based approach using a mixed model with repeated measures (MMRM). The analysis included the fixed, categorical effect of treatment at each visit, and the fixed, continuous effects of baseline FVC at each visit. Visit was treated as the repeated measure, with an unstructured covariance structure used to model the within-patient measurements.

Time frame:
Baseline (day 1) and week 12.
Reported as:
Mean · Milliliter
The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks
MilliliterPlacebo - Antifibrotics at BaselineBI 1015550 - Antifibrotics at BaselinePlacebo - Non-antifibrotics at BaselineBI 1015550 - Non-antifibrotics at Baseline
The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks-77.70 (-124.87 to -30.53)2.72 (-33.46 to 38.89)-95.62 (-157.13 to -34.10)6.10 (-39.67 to 51.88)
Statistical analysis
  • Placebo - Non-antifibrotics at Baseline vs BI 1015550 - Non-antifibrotics at Baseline · Posterior difference: 88.4 · 95% CI 29.5 to 154.2Difference calculated as BI 1015550 - Placebo
  • Placebo - Antifibrotics at Baseline vs BI 1015550 - Antifibrotics at Baseline · Posterior difference: 62.4 · 95% CI 6.3 to 125.5Difference calculated as BI 1015550 - Placebo
SecondaryThe Number of Patients With Treatment Emergent Adverse Event

The number of patients with any adverse event during the on-treatment period.

Time frame:
From the start of treatment till the end of treatment + 7 days residual effect period, an average of 87.4 days.
Reported as:
Count of participants · Participants
The Number of Patients With Treatment Emergent Adverse Event
ParticipantsPlacebo - Antifibrotics at BaselineBI 1015550 - Antifibrotics at BaselinePlacebo - Non-antifibrotics at BaselineBI 1015550 - Non-antifibrotics at Baseline
The Number of Patients With Treatment Emergent Adverse Event51859

Adverse events

Collected over From the start of treatment till the end of treatment + 7 days residual effect period, an average of 87.4 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Antifibrotics at Baseline0/25 (0%)0/25 (0%)10/25 (40%)
BI 1015550 - Antifibrotics at Baseline1/49 (2%)3/49 (6.1%)24/49 (49%)
Placebo - Non-antifibrotics at Baseline0/25 (0%)5/25 (20%)5/25 (20%)
BI 1015550 - Non-antifibrotics at Baseline1/48 (2.1%)3/48 (6.3%)18/48 (37.5%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlacebo - Antifibrotics at BaselineBI 1015550 - Antifibrotics at BaselinePlacebo - Non-antifibrotics at BaselineBI 1015550 - Non-antifibrotics at Baseline
Condition aggravatedGeneral disorders0/252/490/250/48
UrosepsisInfections and infestations0/250/491/250/48
Wound infectionInfections and infestations0/250/491/250/48
Diabetic metabolic decompensationMetabolism and nutrition disorders0/250/491/250/48
Transient ischaemic attackNervous system disorders0/250/491/250/48
Dermatitis exfoliativeSkin and subcutaneous tissue disorders0/250/491/250/48
Cardiac failure congestiveCardiac disorders0/250/490/251/48
COVID-19 pneumoniaInfections and infestations0/250/490/251/48
Lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/250/490/251/48
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/250/490/251/48
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo - Antifibrotics at BaselineBI 1015550 - Antifibrotics at BaselinePlacebo - Non-antifibrotics at BaselineBI 1015550 - Non-antifibrotics at Baseline
DiarrhoeaGastrointestinal disorders4/2515/492/258/48
FatigueGeneral disorders3/251/491/252/48
NasopharyngitisInfections and infestations0/254/490/250/48
CoughRespiratory, thoracic and mediastinal disorders2/254/491/253/48
ConstipationGastrointestinal disorders2/251/490/251/48
NauseaGastrointestinal disorders0/251/492/252/48
RashSkin and subcutaneous tissue disorders2/250/490/250/48
DyspepsiaGastrointestinal disorders1/252/490/253/48
FlatulenceGastrointestinal disorders1/252/491/253/48
AstheniaGeneral disorders0/251/490/253/48

Baseline characteristics

Treated Set (TS): all patients who received at least one dose of trial drug.

Age, Continuous
Age, Continuous(years)Placebo - Antifibrotics at BaselineBI 1015550 - Antifibrotics at BaselinePlacebo - Non-antifibrotics at BaselineBI 1015550 - Non-antifibrotics at BaselineTotal
Mean67.5 ± 10.769.3 ± 6.671.8 ± 9.369.9 ± 8.369.6 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - Antifibrotics at BaselineBI 1015550 - Antifibrotics at BaselinePlacebo - Non-antifibrotics at BaselineBI 1015550 - Non-antifibrotics at BaselineTotal
Female7581434
Male18441734113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo - Antifibrotics at BaselineBI 1015550 - Antifibrotics at BaselinePlacebo - Non-antifibrotics at BaselineBI 1015550 - Non-antifibrotics at BaselineTotal
Hispanic or Latino134513
Not Hispanic or Latino24462143134
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo - Antifibrotics at BaselineBI 1015550 - Antifibrotics at BaselinePlacebo - Non-antifibrotics at BaselineBI 1015550 - Non-antifibrotics at BaselineTotal
American Indian or Alaska Native00000
Asian41241232
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White21372136115
More than one race00000
Unknown or Not Reported00000
Forced vital capacity (FVC)
Forced vital capacity (FVC)(Milliliter)Placebo - Antifibrotics at BaselineBI 1015550 - Antifibrotics at BaselinePlacebo - Non-antifibrotics at BaselineBI 1015550 - Non-antifibrotics at BaselineTotal
Mean2690.000 ± 889.9852875.551 ± 752.8182864.920 ± 1015.1042782.938 ± 835.1042811.946 ± 845.625
08

Study locations

75 sites
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Mayo Clinic, Rochester
    Rochester, Minnesota 55905, United States
  • The Lung Research Center, LLC
    Chesterfield, Missouri 63017, United States
  • Creighton University
    Omaha, Nebraska 68124, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84108, United States
  • Centro de Investigaciones Metabólicas (CINME)
    C.a.b.a, C1027AAP, Argentina
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • LKH-Univ. Hospital Graz
    Graz, 8036, Austria
  • St. Paul's Hospital
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Dr. Georges-L.-Dumont University Hospital Centre
    Moncton, New Brunswick E1C 2Z3, Canada
  • Queen's University
    Kingston, Ontario K7L 2V6, Canada
  • Dr. Syed Anees Medicine Professional Corporation
    Windsor, Ontario N8X 1T3, Canada
  • Centre Hospitalier de l'Universite de Montreal (CHUM)
    Montreal, Quebec H2X 0A9, Canada
  • Instituto Nacional del Tórax
    Providencia, Santiago De Chile, 7500691, Chile
  • Centro de Investigación del Maule
    Talca, 3465586, Chile
  • Peking Union Medical College Hospital
    Beijing, 100032, China
  • The Second Hospital of Jilin University
    Changchun, 130041, China
  • West China Hospital
    Chengdu, 610041, China
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
  • Shanghai Pulmonary Hospital
    Shanghai, 200433, China
  • University Thomayer's Hospital
    Praha 4 - Krc, 140 59, Czechia
  • University Hospital Na Bulovce, Prague
    Praha, 180 81, Czechia
  • Aarhus University Hospital
    Aarhus N, 8200, Denmark
  • Herlev and Gentofte Hospital
    Hellerup, 2900, Denmark
  • Odense University Hospital
    Odense C, 5000, Denmark
  • HYKS Keuhkosairauksien tutkimusyksikkö
    Helsinki, 00290, Finland
  • KYS, Keuhkosairauksien
    Kuopio, 70210, Finland
  • Oulun yliopistollinen keskussairaala
    Oulu, FIN-90220, Finland
  • Tampere University Hospital
    Tampere, 33521, Finland
  • TYKS
    Turku, 20520, Finland
  • Fachkrankenhaus Coswig GmbH
    Coswig, 01640, Germany
  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
    Essen, 45239, Germany
  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Lungenfachklinik Immenhausen
    Immenhausen, 34376, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Athens Medical Center
    Athens, 15125, Greece
  • University General Hospital of Heraklion
    Crete, 71110, Greece
  • Univ. Gen. Hosp. of Patras
    Patras, 26504, Greece
  • Semmelweis University
    Budapest, 1085, Hungary
  • Ospedale Colonnello D Avanzo
    Foggia, 71100, Italy
  • Azienda Ospedaliera Universitaria di Padova
    Padova, 35128, Italy
  • Poli Univ A. Gemelli
    Roma, 00168, Italy
  • A.O.U. Senese Policlinico Santa Maria alle Scotte
    Siena, 53100, Italy
  • Tosei General Hospital
    Aichi, Seto, 489-8642, Japan
  • National Hospital Organization Kyushu Medical Center
    Fukuoka, Fukuoka, 810-8563, Japan
  • Kanagawa Cardiovascular and Respiratory Center
    Kanagawa, Yokohama, 236-0051, Japan
  • National Hospital Organization Kinki-Chuo Chest Medical Center
    Osaka, Sakai, 591-8555, Japan
  • Hamamatsu University Hospital
    Shizuoka, Hamamatsu, 431-3192, Japan
  • Center Hospital of the National Center for Global Health and Medicine
    Tokyo, Shinjuku-ku, 162-8655, Japan
  • The Catholic University of Korea, Bucheon St.Mary's Hospital
    Bucheon, 14647, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Zuyderland Medisch Centrum
    Heerlen, 6419 PC, Netherlands
  • St. Antonius ziekenhuis, locatie Nieuwegein
    Nieuwegein, 3435 CM, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 CE, Netherlands
  • University Clinical Center, Gdansk
    Gdansk, 80-214, Poland
  • Federal state budgetary scientific institution "Research Institute of occupational medicine named after academician N. F. Izmerov
    Moscow, 105275, Russian Federation
  • Moscow 1st State Med.Univ.n.a.I.M.Sechenov
    Moscow, 119992, Russian Federation
  • Emergency Clinical Hospital n. a. N. V. Solovyev, Yaroslavl
    Yaroslavl, 150003, Russian Federation
  • Policlínica Barcelona
    Barcelona, 08006, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de Bellvitge
    L'Hospitalet de Llobregat, 08907, Spain
  • Hospital La Princesa
    Madrid, 28006, Spain
  • Hospital Central de Asturias
    Oviedo, 33011, Spain
  • Hospital Son Espases
    Palma de Mallorca, 07120, Spain
  • Dnyepropyetrovsk Medical Academy, Clinical Hospital No. 6
    Dnyepropyetrovsk, 49074, Ukraine
  • Instit.Phthisiology&Pulmon.na Yanovskiy,Non-Specif.Lung,Kyiv
    Kyiv, 03680, Ukraine
  • Southmead Hospital
    Bristol, BS10 5NB, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
09

References and documents

Publications

  • Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM; 1305-0013 Trial Investigators. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2022 Jun 9;386(23):2178-2187. doi: 10.1056/NEJMoa2201737. Epub 2022 May 15. PubMed 35569036 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Oct 2021, 14 months.

Results were first posted in Nov 2022, 1 year after primary completion.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 14 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2020
First posted
Jun 5, 2020
StartActual
Jul 28, 2020
Primary completionActual
Oct 6, 2021
CompletionActual
Oct 15, 2021
Results first posted
Nov 1, 2022
Last update
Nov 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04419506
Responsible party
Sponsor
First posted
Jun 5, 2020
Start date
Jul 28, 2020
Primary completion
Oct 6, 2021
Completion
Oct 15, 2021
Results posted
Nov 1, 2022
Last update
Nov 1, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion